Table 2 Results of base case NMA: Difference in intervention versus the comparator for CFB in post-dose FEV 1 (mL) at 6Â months, 95% credible intervals, and probability that the intervention is better than the comparator
From: Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis
Intervention | Comparator | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PLACEBO | TIO 18 | SAL 50 | IND 150 | IND 300 | GPM 50 | ||||||||
PLACEBO | estimate | 0 | −202 | −180 | −226 | −276 | −213 | ||||||
95% CrI |  |  | −235 | −167 | −231 | −128 | −287 | −163 | −358 | −192 | −263 | −160 | |
P(better) | Â | Â | <1% | <1% | <1% | <1% | <1% | ||||||
TIO 18 | estimate | 202 | 0 | 23 | −24 | −0.074 | −10 | ||||||
95% CrI | 167 | 235 |  |  | −39 | 82 | −91 | 42 | −158 | 10 | −67 | 45 | |
P(better) | >99% | Â | Â | 78% | 22% | 4% | 33% | ||||||
SAL 50 | estimate | 180 | −23 | 0 | −46 | −96 | −33 | ||||||
95% CrI | 128 | 231 | −82 | 39 |  |  | −117 | 26 | −190 | −1 | −104 | 40 | |
P(better) | >99% | 22% | Â | Â | 9% | 2% | 16% | ||||||
IND 150 | estimate | 226 | 24 | 46 | 0 | −50 | 14 | ||||||
95% CrI | 163 | 287 | −42 | 91 | −26 | 117 |  |  | −140 | 40 | −66 | 92 | |
P(better) | >99% | 78% | 91% | Â | Â | 13% | 65% | ||||||
IND 300 | estimate | 276 | 74 | 96 | 50 | 0 | 64 | ||||||
95% CrI | 192 | 358 | −10 | 158 | 1 | 190 | −40 | 140 |  |  | −33 | 159 | |
P(better) | >99% | 96% | 98% | 87% | Â | Â | 91% | ||||||
GPM 50 | estimate | 213 | 10 | 33 | −14 | −64 | 0 | ||||||
95% CrI | 160 | 263 | −45 | 67 | −40 | 104 | −92 | 66 | −159 | 33 |  |  | |
P(better) | >99% | 67% | 84% | 35% | 9% | Â | Â | ||||||